5 Ht2A Receptor is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Cortical GPCR mediating psychedelic experiences, mood, and cognition
The HTR2A protein is encoded by the HTR2A gene and is a member of the Serotonin receptor family (Class A GPCR). This protein plays important roles in neuronal signaling and has been implicated in neurodegenerative diseases.
| Attribute | Value |
|---|---|
| Protein Name | 5-HT2A Receptor |
| Gene | HTR2A |
| UniProt ID | P28223 |
| PDB Structures | 6WHA, 7WC9 |
| Molecular Weight | 59 kDa |
| Subcellular Localization | Plasma membrane, postsynaptic densities, lipid rafts |
| Protein Family | Serotonin receptor family (Class A GPCR) |
The HTR2A protein contains seven transmembrane helices typical of class A GPCRs, with an extracellular N-terminus and intracellular C-terminus. The ligand-binding pocket is located within the transmembrane domain. Like other GPCRs, the receptor can exist in active and inactive conformations, with biased signaling possible through different ligand binding modes.
The 5-HT2A receptor is a Gq-coupled GPCR highly expressed in cortical pyramidal neurons, particularly in layer 5. Activation of 5-HT2A receptors stimulates phospholipase C signaling, leading to intracellular calcium release and protein kinase C activation. 5-HT2A receptors play crucial roles in modulating NMDA receptor function, regulating synaptic plasticity, and facilitating long-term potentiation (LTP). The receptor is a primary target of classic psychedelic compounds (psilocybin, LSD, DMT) which produce their psychoactive effects through 5-HT2A activation. In the brain, 5-HT2A signaling influences mood, perception, cognition, and emotional processing.
Alzheimer's Disease (reduced receptor density, neuropsychiatric symptoms), Parkinson's Disease (psychosis, dyskinesias), Schizophrenia (altered signaling), Depression (treatment target), hallucinogen persisting perception disorder
Pimavanserin (Nuplazid) - FDA-approved 5-HT2A inverse agonist for Parkinson's disease psychosis. Risperidone and other atypical antipsychotics block 5-HT2A. Psilocybin being studied for treatment-resistant depression and anxiety. 5-HT2A agonists in classical psychedelics produce profound changes in consciousness. Nelotanserin in clinical trials for Lewy body dementia.
The study of 5 Ht2A Receptor has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
5-HT2A receptors are densely distributed in:
5-HT2A is a Gq-coupled receptor:
Alzheimer's Disease:
Parkinson's Disease:
Huntington's Disease:
5-HT2A is the primary target of classic psychedelics:
These compounds produce profound alterations in perception and mood through 5-HT2A activation.